These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 15270633

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Advances in respiratory syncytial virus vaccine development.
    Kneyber MC, Kimpen JL.
    Curr Opin Investig Drugs; 2004 Feb; 5(2):163-70. PubMed ID: 15043390
    [Abstract] [Full Text] [Related]

  • 7. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB, Chen T, Terio NB, Chong SY, Abdullah R, Luckay A, Egan MA, Boutilier LA, Melville K, Lerch RA, Long D, Eldridge JH, Parks CL, Udem SA, Hancock GE.
    Vaccine; 2007 Oct 10; 25(41):7132-44. PubMed ID: 17850933
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
    van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J.
    Rev Med Virol; 2007 Oct 10; 17(1):5-34. PubMed ID: 17004293
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.
    Murphy BR, Collins PL.
    J Clin Invest; 2002 Jul 10; 110(1):21-7. PubMed ID: 12093883
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y, Cyr SL, Burt DS, Anderson R.
    J Clin Virol; 2009 Apr 10; 44(4):287-91. PubMed ID: 19233722
    [Abstract] [Full Text] [Related]

  • 14. Influence of maternal antibodies on neonatal immunization against respiratory viruses.
    Crowe JE.
    Clin Infect Dis; 2001 Nov 15; 33(10):1720-7. PubMed ID: 11595986
    [Abstract] [Full Text] [Related]

  • 15. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
    Antonis AF, van der Most RG, Suezer Y, Stockhofe-Zurwieden N, Daus F, Sutter G, Schrijver RS.
    Vaccine; 2007 Jun 15; 25(25):4818-27. PubMed ID: 17499893
    [Abstract] [Full Text] [Related]

  • 16. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.
    Valosky J, Hishiki H, Zaoutis TE, Coffin SE.
    Clin Diagn Lab Immunol; 2005 Jan 15; 12(1):171-9. PubMed ID: 15643003
    [Abstract] [Full Text] [Related]

  • 17. Response of calves to challenge exposure with virulent bovine respiratory syncytial virus following intranasal administration of vaccines formulated for parenteral administration.
    Ellis J, Gow S, West K, Waldner C, Rhodes C, Mutwiri G, Rosenberg H.
    J Am Vet Med Assoc; 2007 Jan 15; 230(2):233-43. PubMed ID: 17223757
    [Abstract] [Full Text] [Related]

  • 18. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, Burt D, Ward BJ.
    Vaccine; 2007 Jul 20; 25(29):5378-89. PubMed ID: 17561317
    [Abstract] [Full Text] [Related]

  • 19. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
    Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E.
    Vaccine; 2009 Sep 25; 27(42):5913-9. PubMed ID: 19651171
    [Abstract] [Full Text] [Related]

  • 20. Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen.
    Schepens B, Schotsaert M, Saelens X.
    Immunotherapy; 2015 Sep 25; 7(3):203-6. PubMed ID: 25804473
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.